Daijun Xiang1, Hongrui Zhang2, Jie Bai1, Junlong Ma1, Mianyang Li1, Jimin Gao3, Chengbin Wang1. 1. Department of Clinical Laboratory, Chinese People's Liberation Army General Hospital Beijing 100853, China. 2. Ningbo Women & Children's Hospital Ningbo 315031, China. 3. School of Labroratory Medicine and Life Science, Wenzhou Medical College Whenzhou 325000, China.
Abstract
BACKGROUND: A revised classification of chronic kidney disease (CKD) was proposed by the Kidney Disease: Improving Global Outcomes (KDIGO) in 2012. Neutrophil gelatinase-associated lipocalin (NGAL) was considered as one of the most promising biomarkers in clinical nephrology. The aim of this study was to examine the level of NGAL in patients with different impairment of GFR based on the new classification, and to evaluate whether NGAL in serum or urine was associated with different risk categories in CKD patients. METHODS: A cross-sectional study was performed in 240 patients with CKD. NGAL, serum cystatin C, β₂-macroglobulin (β₂-MG), urine α₁-macroglobulin (α₁-MG) and albuminuria were tested in patients with various degrees of renal impairment. RESULTS: Good correlation was found between the NGAL and the cystatin C, β₂-MG and the α₁-MG (r > 0.7). The level of sNGAL in CKD stage 3b was more than that in CKD stage 3a (P = 0.025). The concentration of the NGAL increased progressively with the increasing of risk categories (proposed by the revised CKD classification). The cutoff value of NGAL was calculated from stage 2 to stage 5. ROC analysis showed good AUC (sNGAL > 0.8, uNGAL > 0.7) and high specificity (sNGAL > 87%, uNGAL > 90%) on the cutoff value of NGAL. CONCLUSION: The results confirm NGAL as a useful biomarker in clinical nephrology which is helpful to diagnosis and evaluate the categories for CKD proposed by the KDIGO.
BACKGROUND: A revised classification of chronic kidney disease (CKD) was proposed by the Kidney Disease: Improving Global Outcomes (KDIGO) in 2012. Neutrophil gelatinase-associated lipocalin (NGAL) was considered as one of the most promising biomarkers in clinical nephrology. The aim of this study was to examine the level of NGAL in patients with different impairment of GFR based on the new classification, and to evaluate whether NGAL in serum or urine was associated with different risk categories in CKD patients. METHODS: A cross-sectional study was performed in 240 patients with CKD. NGAL, serum cystatin C, β₂-macroglobulin (β₂-MG), urine α₁-macroglobulin (α₁-MG) and albuminuria were tested in patients with various degrees of renal impairment. RESULTS: Good correlation was found between the NGAL and the cystatin C, β₂-MG and the α₁-MG (r > 0.7). The level of sNGAL in CKD stage 3b was more than that in CKD stage 3a (P = 0.025). The concentration of the NGAL increased progressively with the increasing of risk categories (proposed by the revised CKD classification). The cutoff value of NGAL was calculated from stage 2 to stage 5. ROC analysis showed good AUC (sNGAL > 0.8, uNGAL > 0.7) and high specificity (sNGAL > 87%, uNGAL > 90%) on the cutoff value of NGAL. CONCLUSION: The results confirm NGAL as a useful biomarker in clinical nephrology which is helpful to diagnosis and evaluate the categories for CKD proposed by the KDIGO.
Authors: Manakan B Srichai; Chuanming Hao; Linda Davis; Anastasia Golovin; Min Zhao; Gilbert Moeckel; Steve Dunn; Nada Bulus; Raymond C Harris; Roy Zent; Matthew D Breyer Journal: J Am Soc Nephrol Date: 2008-05-21 Impact factor: 10.121
Authors: Lesley A Stevens; Christopher H Schmid; Tom Greene; Liang Li; Gerald J Beck; Marshall M Joffe; Marc Froissart; John W Kusek; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: Kidney Int Date: 2008-12-31 Impact factor: 10.612
Authors: Sean M Gallagher; R Andrew Archbold; Dan A Jones; Andrew Wragg; Rakesh Uppal; Muhammad M Yaqoob Journal: Kidney Int Date: 2015-11 Impact factor: 10.612